Toxicological comparison of E2a-deleted and first-generation adenoviral vectors expressing alpha1-antitrypsin after systemic delivery.
about
Lifelong elimination of hyperbilirubinemia in the Gunn rat with a single injection of helper-dependent adenoviral vectorModulation of TNFalpha, a determinant of acute toxicity associated with systemic delivery of first-generation and helper-dependent adenoviral vectors.Efficient, long-term hepatic gene transfer using clinically relevant HDAd doses by balloon occlusion catheter delivery in nonhuman primatesOvine adenovirus vectors overcome preexisting humoral immunity against human adenoviruses in vivoRegulation of adenovirus-mediated transgene expression by the viral E4 gene products: requirement for E4 ORF3.Optimization of the helper-dependent adenovirus system for production and potency in vivo.Strategies for reversing drug resistance.Sustained phenotypic correction in a mouse model of hypoalphalipoproteinemia with a helper-dependent adenovirus vector.Hepatocyte gene therapy in a large animal: a neonatal bovine model of citrullinemiaAdministration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboonsGene therapy used for tissue engineering applications.Targeted gene delivery to the lung.Helper-Dependent Adenoviral Vectors.Adenoviral producer cellsGene therapy with helper-dependent adenoviral vectors: current advances and future perspectives.Influence of loxP insertion upstream of the cis-acting packaging domain on adenovirus packaging efficiency.Replication-attenuated Human Adenoviral Type 4 vectors elicit capsid dependent enhanced innate immune responses that are partially dependent upon interactions with the complement system.Development and characterization of novel empty adenovirus capsids and their impact on cellular gene expression.Pilot trial of intravenous infusion of a replication-selective adenovirus (ONYX-015) in combination with chemotherapy or IL-2 treatment in refractory cancer patients.Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity.Sustained expression of human apo A-I following adenoviral gene transfer in mice.Vascular administration of adenoviral vector soaked in absorbable gelatin sponge particles (GSP) prolongs the transgene expression in hepatocytes.Adenoviral vectors: prospects for gene delivery to the central nervous system.
P2860
Q24555782-CD159DCF-6E81-4F85-9AEF-E14961378E44Q33371239-200F8E75-BAE4-4AD6-AA9D-4C226DE9207AQ33713289-92AEC3D3-86C9-4F26-8ED4-4F0089909B2BQ33817933-041E66A5-B35E-4110-99F3-CC290E989FA9Q33819873-36CE887A-3F2E-44CC-ADB2-DFAECEA7EECBQ34996749-6D5AE40B-5F00-4C73-9835-7C4349435846Q35567287-A5B00EA4-9426-4883-A152-ABD30FF007B7Q35607028-9D0CD8C1-BBA5-4F8B-8172-F06EE23A770FQ36455873-B48F199B-0AD1-4F0E-877B-80F5CDEC2C0EQ36557727-C01C8078-D38B-46EB-B2F0-21EB09403700Q36748645-13607DA9-0218-4867-9DAC-0A9044A744BDQ37486747-5EF20FBF-6D2C-4A03-AB56-B9DE967020CFQ37582126-F47E80B5-BA34-4CC2-B05B-B665193F81EFQ37945217-9A969151-3F49-4F0A-A6B4-EDFE9D21145EQ37945218-E3C786D2-CB33-47F0-8732-29257D2AB5C3Q39325003-CB5E370E-60A6-4829-B464-2D179D06FDF5Q40012391-7780D9FB-C522-44D9-B0B9-393EAC3052E3Q40173334-05BEA3DD-E0F4-4852-BBCF-B8EC60EE8801Q40560199-10632026-941F-47BD-8494-643D68FCD476Q40601029-FBE51131-E96C-4C5C-830A-B050894C374DQ43583236-C68F4FED-751E-4599-AC8E-7F49D9121B41Q45172303-2C5CDDD3-460B-452B-994F-51114116167CQ45861863-269AA3F1-508D-4A18-AEE4-222BA50B2B6E
P2860
Toxicological comparison of E2a-deleted and first-generation adenoviral vectors expressing alpha1-antitrypsin after systemic delivery.
description
1998 nî lūn-bûn
@nan
1998 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
Toxicological comparison of E2 ...... ypsin after systemic delivery.
@ast
Toxicological comparison of E2 ...... ypsin after systemic delivery.
@en
type
label
Toxicological comparison of E2 ...... ypsin after systemic delivery.
@ast
Toxicological comparison of E2 ...... ypsin after systemic delivery.
@en
prefLabel
Toxicological comparison of E2 ...... ypsin after systemic delivery.
@ast
Toxicological comparison of E2 ...... ypsin after systemic delivery.
@en
P2093
P1433
P1476
Toxicological comparison of E2 ...... ypsin after systemic delivery.
@en
P2093
Aguilar-Cordova E
Beaudet AL
Langston C
Pestaner J
P304
P356
10.1089/HUM.1998.9.11-1587
P577
1998-07-01T00:00:00Z